|
|
 | | | |
- close
- close
- close
- close
Multiple Sclerosis (MS) Drug Market |
Benzinga
May 21
Comment
Today Biogen
Idec (NASDAQ: BIIB) announced it has submitted a Biologics License
Application (BLA) to the U.S. Food and Drug Administration (FDA) for
approval of PLEGRIDY™ (peginterferon beta-1a), the company's pegylated
...
FierceBiotech
May 20
Comment
Shares of XenoPort skidded lower this morning after the biotech announced its lead experimental drug had decisively failed a late-stage study for spasticity triggered by multiple sclerosis. The troubled biopharma company, which has been struggling...
Benzinga
May 20
Comment
XenoPort (Nasdaq: XNPT) announced today top-line results from its
pivotal Phase 3 clinical trial of arbaclofen placarbil (AP) for the
treatment of patients with spasticity due to multiple sclerosis (MS). The
trial was unsuccessful in demonstrating...
MedPage Today
May 6
Comment
(MedPage Today) -- Multiple sclerosis is more common in blacks than previously thought, especially among women, a population-based study showed.
MedPage Today
Apr 25
Comment
(MedPage Today) -- Patients with clinically isolated syndrome were significantly less likely to progress to definite multiple sclerosis after receiving the oral drug teriflunomide (Aubagio), its manufacturer said.
MedPage Today
Apr 23
Comment
(MedPage Today) -- Progression from clinically isolated syndrome to definite multiple sclerosis was significantly associated with atrophy in the thalamus among patients treated with interferon-beta-1a, researchers said.
MedPage Today
Apr 20
Comment
(MedPage Today) -- Several new medications for multiple sclerosis are in the short-term pipeline, and other treatments, including cell therapies, are on the more distant horizon, according to a well-known MS researcher.
Forbes
Apr 15
Comment
Ampyra, a pill approved to help patients with multiple sclerosis walk, has put Acorda Therapeutics in the small club of profitable biotechnology companies. The drug generated $266 million in annual sales last year, helping Acorda generate a net...
MedPage Today
Apr 11
Comment
(MedPage Today) -- Fetal defects in thymic function and inadequate circulating levels of vitamin D may explain the well recognized influence of birth month on risk for multiple sclerosis, British researchers suggested.
Benzinga
Apr 10
Comment
Omeros Corporation (NASDAQ: OMER) today announced positive data in the most commonly used model for studying the clinical and pathological features of multiple sclerosis (MS), further advancing its development program of GPR17-targeting compounds...
Suggest other news sources for this topic
more ▼WIKI ANALYSIS
WIKI ANALYSIS
| |||||||
